Compared to controls, anti-PD-1 therapy was associated with a significantly lower cumulative incidence of BCC (log-rank test, P < 0.001), while BRAFi treatment showed no significant difference (P = 0.453). The gene discussed is PDCD1; the disease is skin basal cell carcinoma.